drugset / Trial / NCT00203034

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034

Phase 3 Completed 472 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo

Timeline

Start
2000-05
Primary completion
2003-01
Completion
2003-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasagiline Small molecule 0.5 mg Oral
Subject Rasagiline Small molecule 1 mg Oral

Indications